Risk Factors for Poor Tolerance of Ureteral Double-J Stent
Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Feb 4, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the factors that might make it difficult for patients to tolerate a Ureteral Double-J Stent, which is a small tube placed in the urinary tract to help with kidney problems, especially after issues like severe pain from kidney stones. The trial aims to find out why some patients, particularly younger ones, find this treatment uncomfortable and how it affects their daily lives.
To participate in this study, you need to be over 18 years old and require the placement of a Ureteral Double-J Stent. Unfortunately, if you have certain conditions like active cancer, have had the stent for a long time, or would have trouble understanding or answering questions, you wouldn’t be eligible. If you join, you can expect to answer questions about your experience with the stent, which will help researchers learn more about how to improve patient comfort and care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patient over 18 years old
- • patient who need Ureteral Double-J Stenting
- Exclusion Criteria:
- • patient under 18 years old,
- • Iterative change,
- • understanding disorder,
- • inability to answer the questionnaire,
- • refusal of the patient,
- • long-term Ureteral Double-J Stenting (more than 6 month),
- • active cancer.
About Centre Hospitalier Universitaire, Amiens
The Centre Hospitalier Universitaire (CHU) Amiens is a leading academic medical center in France dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on multidisciplinary collaboration, CHU Amiens integrates patient care, education, and research to enhance treatment outcomes and improve patient quality of life. The institution is committed to ethical standards and regulatory compliance in its clinical research endeavors, aiming to contribute significantly to the medical community and the development of new therapeutic approaches. By fostering partnerships with various stakeholders, CHU Amiens strives to translate scientific discoveries into practical applications that benefit patients and healthcare systems alike.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amiens, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported